- Home
- USGO vs QNCX Comparison
USGO vs QNCX Comparison
Compare USGO & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USGO | QNCX |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | Canada | United States |
| Employees | 9 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.0M | 167.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | USGO | QNCX |
|---|---|---|
| Price | $11.15 | $0.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $30.75 | $10.00 |
| AVG Volume (30 Days) | 94.5K | ★ 22.7M |
| Earning Date | 02-24-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.42 | $0.09 |
| 52 Week High | $17.98 | $4.55 |
Technical Indicators
Market Signals| Indicator | USGO | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 27.71 |
| Support Level | $8.34 | $0.09 |
| Resistance Level | $11.20 | $0.98 |
| Average True Range (ATR) | 1.06 | 0.01 |
| MACD | -0.20 | 0.08 |
| Stochastic Oscillator | 2.46 | 18.07 |
Price Performance
Historical ComparisonAbout USGO U.S. GoldMining Inc.
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.